Daily recombinant human GH (rhGH) is currently approved for use in children and adults
with GH deficiency (GHD) in many countries with relatively few side-effects. Nevertheless …

Cytokinin (CTK) has an important regulatory effect on plant morphology, physiology, and
yield, and is one of the main factors regulating nitrogen absorption, transport, and …

Context Somapacitan, a once-weekly reversible albumin-binding GH derivative, is evaluated
in children with GH deficiency (GHD). Objective To demonstrate efficacy and safety of …

Context Growth hormone (GH) replacement requires daily GH injections, which is
burdensome for some adult patients with GH deficiency (AGHD). Objective To demonstrate …

Context Somapacitan is a long-acting GH derivative for treatment of GH deficiency (GHD).
Objective Evaluate the efficacy and tolerability of somapacitan in children with GHD after 2 …

Context Daily growth hormone (GH) injections can be burdensome for patients and carers.
Somapacitan is a long-acting, reversible albumin-binding GH derivative in development for …

Growth hormone (GH) replacement therapy for growth hormone deficiency (GHD) in children
and adults has for over 25 years, until recently, been administered as daily injections. This …

Background: Daily recombinant human growth hormone (rhGH) is approved and marketed
worldwide to treat children and adults with GH deficiency and other conditions. Efficacy of …

Objective Somapacitan is a reversible albumin-binding growth hormone (GH) derivative,
developed for once-weekly administration. This study aimed to evaluate the safety of once …

In 1957, Maurice Raben at Yale was able to isolate and purify growth hormone from
cadaveric pituitary glands. Pituitary growth hormone was the only way to treat children with …